CAS 117928-94-6: Rapastinel

Description: Rapastinel, also known by its developmental code as GLYX-13, is a novel compound primarily investigated for its potential therapeutic effects in treating mood disorders, particularly depression. It is classified as a glycine-site NMDA receptor modulator, which means it interacts with the N-methyl-D-aspartate (NMDA) receptor, a critical component in synaptic plasticity and memory function. Rapastinel is notable for its rapid onset of action and favorable side effect profile compared to traditional antidepressants. It is administered via intravenous infusion and has been studied for its ability to enhance synaptic connectivity and promote neuroplasticity. The compound has shown promise in clinical trials, demonstrating efficacy in alleviating depressive symptoms without the typical side effects associated with conventional antidepressants, such as weight gain or sexual dysfunction. Additionally, its unique mechanism of action distinguishes it from other NMDA receptor antagonists, making it a subject of interest in ongoing research for various neuropsychiatric conditions.

Synonyms:

• Glyx-13

GLYX 13

CAS: 117928-94-6

• Formula: C₁₈H₃₁N₅O₆
• Purity: 99%
• Color and Shape: Solid
• Molecular weight: 413.46864000000005

GLYX-13 trifluoroacetate

CAS: 117928-94-6

• Formula: C₁₈H₃₁N₅O₆·xC₂HF₃O₂
• Purity: ≥ 98.0%
• Color and Shape: White to tan powder
• Molecular weight: 413.47 (free base)

Rapastinel

CAS: 117928-94-6

Rapastinel (TPPT-amide) (GLYX-13) is an N-methyl-D-aspartate receptor (NMDAR) modulator.

• Formula: C₁₈H₃₁N₅O₆
• Purity: 98%
• Color and Shape: Solid
• Molecular weight: 413.47

GLYX 13

CAS: 117928-94-6

GLYX-13 is a novel, orally bioavailable, small-molecule drug that has been shown to have anti-cancer …

• Formula: C₁₈H₃₁N₅O₆
• Purity: Min. 95%
• Molecular weight: 413.47 g/mol